Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio, Inc.

Therini Bio

Therini Bio, Inc. | 1,720 followers on LinkedIn. Immunotherapies for NEUROINFLAMMATION in diseases driven by vascular dysfunction  | Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. The Company is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer’s disease (AD) and Diabetic Macular Edema (DME), where destructive neuroinflammation plays a central role in the disease process. The foundational science was licensed based on technology discovered in Katerina Akassoglou’s, Ph.D., laboratories at the Gladstone Institutes at the University of California San Francisco (UCSF) and formerly the University of California San Diego (UCSD).

Professor @ Gladstone & UCSF | Neuroimmunology, Neuroscience, Vascular Biology

Katerina Akassoglou

Head of Translational Sciences at Therini Bio

Aaron Kantor

General Partner & Managing Director at DFV | Healthcare VC, Entrepreneur, & Board Director

Sourav Kole

Biotech executive, company builder and board member

Tara Nickerson

Congrats to Therini founder Katerina Akassoglou and her collaborators on this significant research published today in Nature. This study further highlights the importance of therapies targeting neuroinflammation resulting from fibrin, such as those currently being developed by Therini for Alzheimer's and retinal diseases. https://lnkd.in/g8Y-akS7

Therini Bio team at ARVO this week shared updates on our pioneering approach to halt chronic neuroinflammation in diseases caused by vascular injury. Aaron Kantor , Joel Naor, MD, MSc, MBA #ARVO2024 #neuroinflammation #fibrin https://lnkd.in/g-6wdneD

Further research demonstrating how fibrin triggers neuroinflammation by JaeKyu Ryu and Therini Founder Katerina Akassoglou . Therini is developing a first-in-class immunotherapy, currently in Phase 1 studies, to neutralize the toxic effects of fibrin.

Congrats to Therini Bio's scientific founder Katerina Akassoglou on this well-deserved recognition! Stemming from this pioneering research, Therini is developing THN391 to target fibrin-driven neuroinflammation in diseases involving loss of vascular integrity including Alzheimer's disease and Diabetic Macular Edema.

We celebrate Katerina Akassoglou for her pioneering research around the role of fibrin-driven inflammation underlying a range of diseases that involve vascular dysfunction, and discovery of a fibrin-targeting immunotherapy approach to protect against neuroinflammation and neurodegeneration.

THER

COM:THERINIBIO

Therini Bio

locale

market

industry

website

crunchbase

linkedin

peer of

competitor of

Metrics